Annual Report and Accounts for the year ended 30 June 2023
About Us
Dechra is a global specialist in veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.
Our Purpose Framework
Our purpose is the sustainable improvement of global animal health and welfare.
How We Make a Difference
We believe that our success is based upon providing our stakeholders with a clear strategic plan that is aligned with our Purpose. We then deliver this strategy by focusing on three strategic enablers, all of which are underpinned by our Sustainability strategy.
Our Culture and Values
Everything we do is underpinned by our Culture and Values. They are important to us and have helped drive the Group’s success. We believe that our Values encapsulate our business ethics and set out the standards that we wish to achieve and ultimately exceed. They outline the type of people we are, the services we provide and the way we aim to do business. We deliver high quality products and services to veterinarians worldwide through our employees and a network of third parties with the aim of sustainably improving global animal health and welfare.
Our Values are a consistent part of how we lead the Dechra business. From recruitment through to investment in the development and growth of our employees we use our Values to describe what matters at Dechra. To maintain that integrity we have formed a small group of communications ambassadors who have helped us build the content for the Group intranet, further enabling us to demonstrate how the Values are being lived every day.
As the Dechra business grows through acquisition, we have recognised the importance of onboarding new employees into the Dechra way and enabling them to share and build on our Values as a route to unlocking value and success.
The Importance of Our Stakeholders
Engagement with stakeholders is a vital component of our long term sustainability and success, and helps make the business stronger and more resilient. We have identified six key stakeholder groups that we believe are important to engage with regularly to continue to make Dechra successful:
- People: our employees are our greatest asset and we aim to make Dechra a great and safe place to work by attracting, retaining and developing talent;
- Veterinary Professionals: we engage with veterinary professionals to improve animal health and welfare through the use of our innovative and effective products supplemented by daily engagement with our people, utilisation of the Dechra Academy, lunch and learns and technical support helpline;
- Shareholders: engagement is key to instilling trust and confidence, whilst also facilitating informed investment decisions;
- Suppliers: we aim to trade with honesty and integrity, and to source sustainable, ethically produced, quality raw materials and finished products;
- Communities: we believe it is important to give something back to the communities in which we operate; and
- Regulatory Authorities: it is vital to our business that our products meet the highest possible safety and quality standards and we work collaboratively with the relevant bodies worldwide.
Our Integrated Approach to Sustainability
This year, we have made a change to how we think about and present the interaction between our corporate strategic enablers and our Sustainability strategy. Rather than ESG being a standalone Strategic Enabler we have taken the opportunity to reposition our Sustainability strategy such that it now serves as a fundamental underpin to delivering our corporate growth strategy and, ultimately, our Purpose.
Our Impact
Since 2020, we have chosen to link our Sustainability strategy to the United Nations Sustainable Development Goals. This allows us to contribute to a number of goals through our Making a Difference plan.
Our Structure
Corporate
Product Development and Regulatory Affairs
(PDRA)Dechra Pharmaceutical Manufacturing and Supply
(DPM&S)
Corporate
Number of Employees 87
90% of Corporate employees are located out of the UK, with the majority out of the Northwich office. Corporate includes Group Finance, Company Secretarial, Compliance and Legal, Group HR, Sustainability, Group IT and Digital.
Product Development and Regulatory Affairs (PDRA)
Number of Employees 228
Develops Dechra’s own branded veterinary product portfolio of novel, generic and generic plus pharmaceuticals and related medical products. It obtains licences for our products, manages post approval adverse event reporting, periodic product renewals and other activities required to maintain the product licences in every country that we operate.
Laboratories are located in UK, Netherlands and Croatia with teams also located in Australia, Brazil and US.
Dechra Pharmaceuticals Manufacturing and Supply (DPM&S)
Number of Employees 901
Manufactures and supplies Dechra’s product range efficiently and to the highest quality standards maintaining a reliable supply chain. Approximately 50% of Dechra’s pharmaceuticals are produced within our eight manufacturing sites with the remaining 50% managed through external supply relationships.
In Europe, our manufacturing sites are located in Skipton, UK, Bladel, the Netherlands and Zagreb, Croatia. We also have three sites in the United States with facilities in Fort Worth, Melbourne and Pomona, and a further two sites located in Brazil and Australia.
Dechra Veterinary Products Europe
(DVP EU)Dechra Veterinary Products International
(DVP International)Dechra Veterinary Products North America
(DVP NA)
Dechra Veterinary Products Europe (DVP EU)
45.1% of Revenue
Number of Employees 561
Markets and sells Dechra’s products in 18 countries via our own legal entities and via two distributors. It has sales teams in Austria, Belgium, BosniaHerzegovina, Croatia, Denmark, Finland, France, Ireland, Italy, Germany, Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden, UK. The business has opened an office in Switzerland and is due to commence trading during the 2024 financial year.
Products are sold across all key categories of CAP, Equine and FAP. DVP EU also markets a range of specialist, therapeutic pet diets, branded Specific.
The major geographies are France, Germany, the Netherlands and UK.
Dechra Veterinary Products International (DVP International)
11.4% of Revenue
Number of Employees 385
Markets and sells Dechra’s veterinary products in Australia, New Zealand, Serbia, South Korea and Brazil through our own legal entities and via 80 distributors to countries worldwide (including Eastern Europe). DVP ANZ manufactures, markets and sells branded non-proprietary prescription and other related companion animal products. DVP Brazil predominately manufactures, markets and sells vaccines in Brazil, other South American markets and some Asian countries.
The products sold by DVP International vary significantly by country, largely due to the different rates at which the CAP market is developing in each territory.
The major geographies are Australia, New Zealand, Brazil and South Korea.
Dechra Veterinary Products NA (DVP NA)
43.5% of Revenue
Number of Employees 295
Markets and sells Dechra’s veterinary products in Canada, Mexico and the US via our own legal entities and via six distributors to other countries in Central America.
DVP US predominantly markets CAP and Equine medicines. Following the acquisition of Med-Pharmex in August 2022, it also now sells a small range of FAP products. DVP Canada and DVP Mexico both market CAP and Equine medicines, whilst the latter also sells FAP and exports to Central America countries.
The major geographies are Canada, Mexico and US.
Corporate
Number of Employees 87
90% of Corporate employees are located out of the UK, with the majority out of the Northwich office. Corporate includes Group Finance, Company Secretarial, Compliance and Legal, Group HR, Sustainability, Group IT and Digital.
Product Development and Regulatory Affairs (PDRA)
Number of Employees 228
Develops Dechra’s own branded veterinary product portfolio of novel, generic and generic plus pharmaceuticals and related medical products. It obtains licences for our products, manages post approval adverse event reporting, periodic product renewals and other activities required to maintain the product licences in every country that we operate.
Laboratories are located in UK, Netherlands and Croatia with teams also located in Australia, Brazil and US.
Dechra Pharmaceuticals Manufacturing and Supply (DPM&S)
Number of Employees 901
Manufactures and supplies Dechra’s product range efficiently and to the highest quality standards maintaining a reliable supply chain. Approximately 50% of Dechra’s pharmaceuticals are produced within our eight manufacturing sites with the remaining 50% managed through external supply relationships.
In Europe, our manufacturing sites are located in Skipton, UK, Bladel, the Netherlands and Zagreb, Croatia. We also have three sites in the United States with facilities in Fort Worth, Melbourne and Pomona, and a further two sites located in Brazil and Australia.
Dechra Veterinary Products Europe (DVP EU)
45.1% of Revenue
Number of Employees 561
Markets and sells Dechra’s products in 18 countries via our own legal entities and via two distributors. It has sales teams in Austria, Belgium, BosniaHerzegovina, Croatia, Denmark, Finland, France, Ireland, Italy, Germany, Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden, UK. The business has opened an office in Switzerland and is due to commence trading during the 2024 financial year.
Products are sold across all key categories of CAP, Equine and FAP. DVP EU also markets a range of specialist, therapeutic pet diets, branded Specific.
The major geographies are France, Germany, the Netherlands and UK.
Dechra Veterinary Products International (DVP International)
11.4% of Revenue
Number of Employees 385
Markets and sells Dechra’s veterinary products in Australia, New Zealand, Serbia, South Korea and Brazil through our own legal entities and via 80 distributors to countries worldwide (including Eastern Europe). DVP ANZ manufactures, markets and sells branded non-proprietary prescription and other related companion animal products. DVP Brazil predominately manufactures, markets and sells vaccines in Brazil, other South American markets and some Asian countries.
The products sold by DVP International vary significantly by country, largely due to the different rates at which the CAP market is developing in each territory.
The major geographies are Australia, New Zealand, Brazil and South Korea.
Dechra Veterinary Products NA (DVP NA)
43.5% of Revenue
Number of Employees 295
Markets and sells Dechra’s veterinary products in Canada, Mexico and the US via our own legal entities and via six distributors to other countries in Central America.
DVP US predominantly markets CAP and Equine medicines. Following the acquisition of Med-Pharmex in August 2022, it also now sells a small range of FAP products. DVP Canada and DVP Mexico both market CAP and Equine medicines, whilst the latter also sells FAP and exports to Central America countries.
The major geographies are Canada, Mexico and US.
